The London-based startup Aparito is developing wearable technologies and mobile apps to remove some of this discomfort experienced by patients, with a special focus on people living with a rare disease. Their watch collects relevant data from the wearer, and sends the information to a smartphone via Bluetooth. The information is uploaded to the cloud so clinicians can analyze and monitor the patient’s progress. The app can also be updated with patient-added data, such as dosage change or symptoms like seizures, reducing human error when patients are asked when or what triggered a specific symptom, or what day they forgot their medication.
The company was founded by Dr. Elin Haf Davies, who has worked as a children’s nurse for many years, experiencing the frustration of relying on sterile snapshots of data that tell you how a patient is feeling during a hospital visit. The data was simply not enough to help patients better manage their disease in their day to day life at home.
With Aparito, patients will no longer be tied to constant hospital visits, and the focus that the company has on children with rare diseases, also differentiate them from other similar wearables and apps. The real-time monitoring give more accurate data than a snapshot hospital test, which could be crucial for monitoring complex diseases and its progression. And maybe most importantly, it is a powerful tool that engage patients, increasing the understanding of their health, improving patient-doctor communication, ultimately giving them a higher level of involvement in their own care.
For clinicians, the technology becomes a tool to monitor their patients, enabling them to intervene if they identify problems with for example medication or disease progression. This also means that they can spend their time on those patients with most critical need, increasing efficiency and potentially lowering overall healthcare costs.
According to IHS Technology, more than 4 million patients globally will remotely monitor their health condition by 2020. Aparito’s goal is to develop wearables and apps for two new diseases each year, and with funding from Actelion Pharmaceuticals, they have partnered with the Niemann-Pick Association in the UK and Gauchers Association to create solutions specifically for patients with these diseases. They are also supported by Bethnal Green Ventures, IBM, UnLtd and Velocity Health, and was named among the 2015 Nominet Trust 100 – a global celebration of the 100 most inspiring uses of digital technology for social good. In 2016, Aparito was a finalist in the UK MassChallenge.